JP2022544559A5 - - Google Patents

Info

Publication number
JP2022544559A5
JP2022544559A5 JP2022509131A JP2022509131A JP2022544559A5 JP 2022544559 A5 JP2022544559 A5 JP 2022544559A5 JP 2022509131 A JP2022509131 A JP 2022509131A JP 2022509131 A JP2022509131 A JP 2022509131A JP 2022544559 A5 JP2022544559 A5 JP 2022544559A5
Authority
JP
Japan
Prior art keywords
cancer
compound
pharmaceutical composition
pharmaceutically acceptable
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544559A (ja
JP7566010B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046329 external-priority patent/WO2021030671A1/en
Publication of JP2022544559A publication Critical patent/JP2022544559A/ja
Publication of JP2022544559A5 publication Critical patent/JP2022544559A5/ja
Application granted granted Critical
Publication of JP7566010B2 publication Critical patent/JP7566010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509131A 2019-08-14 2020-08-14 四環式化合物及びそれらの塩、組成物、ならびにそれらの使用方法 Active JP7566010B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962886621P 2019-08-14 2019-08-14
US62/886,621 2019-08-14
US201962946774P 2019-12-11 2019-12-11
US62/946,774 2019-12-11
PCT/US2020/046329 WO2021030671A1 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Publications (3)

Publication Number Publication Date
JP2022544559A JP2022544559A (ja) 2022-10-19
JP2022544559A5 true JP2022544559A5 (https=) 2023-08-22
JP7566010B2 JP7566010B2 (ja) 2024-10-11

Family

ID=74568302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509131A Active JP7566010B2 (ja) 2019-08-14 2020-08-14 四環式化合物及びそれらの塩、組成物、ならびにそれらの使用方法

Country Status (12)

Country Link
US (1) US20210046071A1 (https=)
EP (1) EP4013421A4 (https=)
JP (1) JP7566010B2 (https=)
KR (1) KR20220130085A (https=)
CN (1) CN114599368A (https=)
AU (1) AU2020328590B2 (https=)
BR (1) BR112022002784A2 (https=)
CA (1) CA3151112A1 (https=)
IL (1) IL290626A (https=)
PH (1) PH12022550360A1 (https=)
TW (1) TW202114694A (https=)
WO (1) WO2021030671A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928100B2 (en) * 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
ES2754207T3 (es) * 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
JP7017509B2 (ja) * 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP7492002B2 (ja) Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法
JP2022121594A5 (https=)
JP2022544559A5 (https=)
WO2024088273A1 (zh) 一种萘酰胺化合物治疗kras突变相关疾病的用途
JP2006523216A5 (https=)
JP2010189446A (ja) 肝臓癌の発症予防のための医薬
JP2025098190A5 (https=)
SE462076B (sv) Antitoemoerkomposition innehaallande diltiazem och ett antitoemoermedel som utvaeljs bland vincristin och doxorubicin, samt anvaendning av diltiazem foer framstaellning av ett antitumoermedel med potentierad verkan
JP2021511344A5 (https=)
AU2004220205B2 (en) Antitumor effect potentiator and antitumor agent
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
JP2013523867A5 (https=)
JP5210888B2 (ja) 黒色腫の治療のためのガリウム(iii)錯体の使用
JP2022502378A5 (https=)
EP4176880A1 (en) Pharmaceutical composition for preventing or treating cancer comprising 3-ketoacyl-coa thiolase inhibitor and carnitine acylcarnitine carrier inhibitor
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
WO2021025148A1 (ja) 抗ccr4抗体抵抗性のがんの治療剤
WO2024160057A1 (zh) 长效β2AR激动剂在制备治疗癌症药物中的应用
JP5570429B2 (ja) デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法
WO2020045461A1 (ja) ピラゾロ[3,4-d]ピリミジン化合物を有効成分とする治療剤
JP2020535112A (ja) Midh1阻害剤とdna低メチル化剤(hma)との組合せ
WO1997024126A1 (en) Malignant tumor metastasis inhibitors
RS52668B (sr) Pojačivač antitumornog efekta, antitumorno sredstvo i postupak lečenja kancera
CN109481687B (zh) 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合